

Bioactive constituents of *Verbena officinalis* alleviate inflammation and enhance killing efficiency of natural killer cells

3 Xiangdong Dai ^{1*}, Xiangda Zhou ^{2*}, Rui Shao ^{1*}, Renping Zhao ², Archana K.
4 Yanamandra ^{2,3}, Zhimei Xing ¹, Mingyu Ding ⁴, Junhong Wang ⁵, Han Zhang ¹, Yi Wang
5 ⁶, Qi Zheng ¹, Peng Zhang ¹, Bin Qu ^{2#}, Yu Wang ^{1,5#}

¹ State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; ² Department of Biophysics, Center for Integrative Physiology and Molecular Medicine (CIPMM), School of Medicine, Saarland University, Homburg; ³ Leibniz Institute for New Materials, Saarbrücken, Germany; ⁴ Institute for Immunology, School of Medicine, Tsinghua University, Beijing 100084, China ⁵ School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China; ⁶ Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.

15 * equal contribution

16 # Corresponding author:

17 Bin Qu
18 Department of Biophysics
19 Center for Integrative Physiology and Molecular Medicine (CIPMM)
20 School of Medicine, Saarland University
21 66421 Homburg, Germany.
22 Tel: +49 6841 16 16310, Fax: +49 6841 16 16302
23 Email: bin.qu@uks.eu

25 Yu Wang
26 School of Integrative Medicine
27 Tianjin University of Traditional Chinese Medicine
28 301617 Tianjin, China
29 Tel.: +86 22 59596171, Fax: +86 22 27493265
30 E-mail: wangyu@tjutcm.edu.cn

31

32

33

34 **Abstract**

35 Natural killer (NK) cells play a key role in eliminating pathogen-infected cells. *Verbena*
36 *officinalis* (*V. officinalis*) has been used as a medical plant in traditional and modern
37 medicine, exhibiting anti-tumor and anti-inflammation activities, but its roles in
38 immune responses still remains largely elusive. In this work, investigated the regulation
39 of inflammation and NK functions by *V. officinalis* extract (VO-extract). In an influenza
40 virus infection mouse model, oral administration of VO-extract alleviated lung injury,
41 promoted maturation and activation of NK cells residing in the lung, and decreased the
42 levels of inflammatory cytokines (IL-6, TNF- α and IL-1 β) in the serum. We further
43 analyzed the impact of five bioactive components of VO-extract on NK killing
44 functions. Among them, Verbenalin enhanced NK killing efficiency significantly as
45 determined by real-time killing assays based on plate-reader or high-throughput live-
46 cell imaging in 3D using primary human NK cells. Further investigation showed that
47 treatment of Verbenalin accelerated killing processes by reducing the contact time of
48 NK cells with their target cells without affecting NK proliferation, expression of
49 cytotoxic proteins, or lytic granule degranulation. Together, our findings reveal that low
50 doses of *V. officinalis* can achieve a satisfactory anti-inflammation effect against viral
51 infection *in vivo*, and *V. officinalis* regulates activation, maturation and killing functions
52 of NK cells. NK killing efficiency is enhanced by Verbenalin from *V. officinalis*,
53 suggesting a promising potential of verbenalin to fight viral infection.

54

55 **1. Introduction**

56 *Verbena officinalis* L. (*V. officinalis*), also known as common vervain, is a medicinal
57 herb, widespread throughout the globe, mainly in the temperate climate zone^[1]. In
58 China, *V. officinalis* is widely distributed in the southern part of the Yellow River and
59 has been widely used not only as traditional Chinese medicine for the treatment of
60 rheumatism, bronchitis, depression, insomnia, anxiety, liver and gallbladder diseases
61 **Error! Reference source not found**, but also in food and cosmetics with a long-standing record
62 for validated safety^{**Error! Reference source not found**}. Flavonoids, terpenoids, phenolic acids,
63 phenylpropanoids and iridoids are its mainly identified bioactive constituents^[2]. Recent
64 reports suggest that *V. officinalis* has various scientifically proven activities, such as
65 anti-oxidation, anti-bacteria, anti-fungi, and anti-inflammation properties^[6].

66 Inflammation is a immune response triggered by numerous factors, including virus,
67 bacteria, and transformed cells. During inflammation, permeability of blood vessels is
68 enhanced, facilitating recruitment of immune cells to the inflammation site. Recruited
69 immune cells release cytokines to further activate and recruit other effector immune
70 cells. Inflammatory responses play an essential role in fighting pathogens. However,
71 uncontrolled inflammatory responses can lead to severe consequences for example
72 organ functional failure especially in lung and life-threatening cytokine storm
73 syndrome. Innate immune cells are the main players to initiate inflammation responses.

74 In the innate immune system, natural killer (NK) cells are specialized immune killer
75 cells, which play a key role in eliminating tumorigenic and pathogen-infected cells.
76 After viral infection, NK cells are recruited to the lungs and play an essential role in the

77 immune response to fight pathogens. Several studies highlight the pivotal role of NK
78 cells in the control of infection of influenza virus H1N1. Defects in NK cell activity or
79 depletion of NK cells result in delayed viral clearance and increased morbidity and
80 mortality [Error! Reference source not found.](#). However, there are also examples in which NK cells
81 exacerbate morbidity and pathology during lethal dose influenza virus infection in mice
82 [Error! Reference source not found.](#), indicating that overactivation of NK cells may lead to
83 undesirable effects. In addition, NK cells play important roles in bridging the innate
84 and adaptive immune responses to viral infection [Error! Reference source not found.](#).

85 In this work, we investigated the anti-inflammation effect of VO-extract *in vivo* with
86 low (0.5 g/kg) and high (1 g/kg) doses using a viral infection mouse model. We found
87 that both doses significantly reduced viral infection-induced release of inflammatory
88 cytokines (TNF α , IL-6, and IL-1 β). Of note, the low dose exhibited a better protection
89 of the lung tissue and could induce higher level of NK activation. Further analysis of
90 bioactive constituents from *V. officinalis* revealed that Verbenalin substantially
91 enhanced killing efficiency of NK cells.

92 **2. Materials and Methods**

93 *2.1. Preparation of VO-extract*

94 The *Verbena officinalis L.* was obtained from Anhui Zehua China Pharmaceutical Slices
95 Co., Ltd. The whole plants of *Verbena officinalis L.* (4.5 kg) were extracted with 4.5 L
96 70% ethanol for 2 hours by refluxing extraction repeated for three times. The combined
97 extract was filtrated with ceramic membranes. The filtration was then concentrated with
98 by vacuum evaporation apparatus at a temperature not exceeding 45 °C. Then the

99 extract was lyophilized to obtain the VO-extract powder.

100 *2.2. UPLC-Q-TOF-MS analysis*

101 An Agilent 1290 UHPLC system (Agilent Technologies Inc., Palo Alto, CA, USA)

102 coupled to an Agilent 6520 Q-TOF instrument with electrospray ionization (ESI) source

103 was used for the quantitative analysis. The ACQUITY UPLC® BEH C18(2.1×150 mm,

104 1.7 μ m; Waters, Milford, MA, USA) was used for chromatographic separation. The

105 mobile phase consisted of 0.1% aqueous formic acid (A) and methanol (B). The elution

106 conditions involved holding the starting mobile phase at 95% A and 5% B and applying

107 a gradient of 5% A and 95% B for 35 min. The flow rate was 0.3 mL/min, and the

108 injection volume for all the sample was 2 μ L. Experiments were performed in positive

109 and negative ESI mode with the following parameters: temperature of ESI, 100 °C;

110 collision energy, 10 V; collision pressure, 135V; fragmentor voltage, 135 V; nebulizer

111 gas, 40.0 psi; dry gas, 11.0 L/min at a temperature of 350 °C; scan range, m/z 100-1700.

112 *2.3. Mice and virus.*

113 6–10 week old female C57BL/6 mice(20 to 25 g body weight) were purchased from

114 Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China), and

115 housed in standard microisolator cages in a centralized animal care facility. Animal care

116 and experimental procedures were performed in accordance with experimental-animal

117 guidelines. Mice were given ad libitum access to food and water, and subject to 12 h

118 light/dark cycling. All mice were adapted to the environment for seven days before the

119 study. Virus (H1N1) were frozen at -80°C.

120 *2.4. Virus infection*

121 Mice were anesthetized with isoflurane and intranasally inoculated with H1N1 in 40
122 μ L PBS. We inoculated mice with 100 PFU H1N1. The number of mice in each group
123 ranged from 6 to 8. The mice in the Vehicle group were intranasally challenged with 40
124 μ L PBS. All the animal experiments were approved and made to minimize suffering
125 and to reduce the number of animals used.

126 *2.5. VO-extract administration*

127 VO-extract (VL: 492mg/kg; VH: 984mg/kg) was administered by oral gavage once
128 daily, 3 days for the duration of treatment. VO-extract was freshly prepared each day
129 and stored at 4 °C. The mice in the Vehicle group were orally administered with distilled
130 water simultaneously. On the third day, the mice were sacrificed, and their blood and
131 lung were collected for further analysis. Meanwhile, mice were monitored and body
132 weight changes were recorded.

133 *2.6. Flow cytometry assay*

134 After blocking the receptor with anti-CD16/CD32, extracellular markers were stained,
135 cells were fixed. These cells were incubated with specific surface-binding antibodies
136 for 30 min at 4°C. Samples were analyzed using BD FACScalibur and FlowJo software.
137 Cells were gated according to forward scatter and side scatter, and cell types were
138 identified by phenotype as follows: for NK cells:CD45, NK1.1, CD11b, CD69.

139 *2.7. Hematoxylin–eosin (HE) staining*

140 For the assay of lung pathological changes, the mice were sacrificed on the third day,
141 and the lung tissues of the infected mice were collected, fixed in 10% buffered formalin,
142 and embedded in paraffin. Each tissue was cut into 4 μ m sections and stained with

143 hematoxylin and eosin. Subsequently, Lung injury was evaluated according to a
144 quantitative scoring system assessing infiltration of immune cells, thickening of
145 alveolar walls, disrupted lung parenchyma^[14]. Scoring was performed by three
146 researchers independently according to standard protocols.

147 *2.8. Detection of IL-6, TNF- α and IL-1 β levels in serum*

148 Blood samples were centrifuged at 3000 rpm and 4 °C for 15 min to obtain the sera.
149 The contents of IL-6, TNF- α and IL-1 β in the sera were measured by ELISA following
150 the manufacturer's instructions and by using a microplate reader. The contents of these
151 cytokines were determined by establishing standard curves.

152 *2.9. NK Cell preparation and cell culture*

153 Primary human NK cells were isolated from peripheral blood mononuclear cells
154 (PBMCs) of healthy donors using Human NK Cell Isolation Kit (Miltenyi). The isolated
155 NK cells were cultured in AIM V medium (ThermoFischer Scientific) with 10% FCS
156 and 100 U/ml of recombinant human IL-2 (Miltenyi). K562 and K562-pCasper cells
157 were cultured in RPMI-1640 medium (ThermoFischer Scientific) with 10% FCS. For
158 K562-pCasper cells, 1.25mg/ml G418 was added. All cells were kept at 37 °C with 5%
159 CO₂.

160 *2.10. Real-time killing assay*

161 Real-time killing assay was conducted as reported previously^{Error! Reference source not found.}.
162 Briefly, target cells (K562 cells) were loaded with Calcein-AM (500 nM, ThermoFisher
163 Scientific) and settled into a 96-well plate (2.5×10^4 target cells per well). NK cells were
164 subsequently added with an effector to target (E:T) ratio of 2.5:1 if not otherwise

165 mentioned. Fluorescence intensity was determined by GENios Pro micro-plate reader
166 (TECAN) using the bottom-reading mode at 37°C every 10 min for 4 hours. Target lysis
167 (t) % = 100 × (F_{live}(t)-F_{exp}(t))/(F_{live}(t)-F_{lysed}(t)). (F: fluorescence intensity)

168 *2.11. 3D killing assay and live cell imaging*

169 Briefly, target cells (K562-pCasper cells) were embedded into 2 mg/ml of pre-chilled
170 neutralized Bovine type I collagen solution (Advanced Biomatrix) in a 96 well plate.
171 The collagen was solidified at 37°C with 5% CO₂ for 40 min. NK cells were
172 subsequently put on top of collagen as effector cells. The cells were visualized using
173 ImageXpress Micro XLS Widefield High-Content Analysis System (Molecular
174 Devices) at 37 °C with 5% CO₂. For 3D killing assay, as described previously^[18], the
175 killing events were visualized every 20 min for 36 hours, and live target cell numbers
176 were normalized to hour 0 based on area. For live cell imaging to determine time
177 required for killing and the average kills per NK cell, the cells were visualized every 70
178 sec for 14 hours and tracked manually. Image J software was used to process and
179 analyze the images.

180 *2.12. Proliferation assay*

181 To examine proliferation, freshly isolated primary human NK cells were labelled with
182 CFSE (1 μM, ThermoFischer Scientific) and then stimulated with recombinant human
183 IL-2 in presence of Verbenalin at indicated concentrations for 3 days. Fluorescence was
184 determined with a FACSVerse™ flow cytometer (BD Biosciences) and analyzed with
185 FlowJo v10 (FLOWJO, LLC).

186 *2.13. Determination of cytotoxic protein expression*

187 To test perforin and granzyme B expression, NK cells were fixed in pre-chilled 4%
188 paraformaldehyde. Permeabilization was carried out using 0.1% saponin in PBS
189 containing 0.5% BSA and 5% FCS. FACSVerse™ flow cytometer (BD Biosciences)
190 was used to acquire data. FlowJo v10 (FLOWJO, LLC) was used for analysis.

191 *2.14. CD107a degranulation assay*

192 For degranulation assay, K562 cells were settled with vehicle-treated or Verbenalin-
193 treated NK cells in the presence of Brilliant Violet 421™ anti-human CD107a (LAMP1)
194 antibody (Biolegend) and GolgiStop™ (BD Biosciences). The incubation were carried
195 out at 37°C with 5% CO₂ for 4 hours. The cells were then stained with PerCP anti-
196 human CD16 antibody (Biolegend) and APC mouse anti-human CD56 antibody (BD
197 Biosciences) to define NK cells. Data was obtained with a FACSVerse™ flow
198 cytometer (BD Biosciences) and was analyzed with FlowJo v10 (FLOWJO, LLC).

199 *2.15. Statistical analysis*


200 Data were analyzed using the SPSS version 19.0 and the GraphPad Prism software
201 5.0 and presented as mean \pm standard deviation (SD). Significant differences among
202 the multiple group comparisons were performed using one-way analysis of variance
203 (ANOVA), and the ANOVA comparisons were analyzed through Tukey's honest
204 significant difference test, whereas data with a partial distribution were examined
205 using the nonparametric Kruskal–Wallis test with Dunn's multiple comparison as
206 post-test. A p value < 0.05 indicated significant difference.

207 **3. Results**

208 *3.1. VO-extract attenuates the acute lung damage induced by viral infection*

209 Lung damage induced by infection of virus, for example influenza or SARS-CoV
210 (severe acute respiratory syndrome coronavirus)-1/2 can cause severe breathing
211 problems or even respiratory failure^[19]. Infection-induced acute lung damage can result
212 in persist lung abnormalities such as pulmonary fibrosis, leading to long-term
213 impairments in the respiratory system for the patients recovered from the infection^[20].
214 Infection-induced acute lung damages are, to a large extent, owed to a massive
215 inflammation initiated by the overactivated immune system. The well-established anti-
216 inflammation activity of *V. officinalis* prompted us to examine its effect on infection-
217 induced lung damage. To this end, we infected C57BL/6J mice with an influenza virus
218 A/PR8/34 (H1N1) and intragastrically administrated VO-extract upon viral infection
219 once per day for 3 days (Figure 1A). We chose the low dose (0.5 g/kg) and the high
220 dose (1 g/kg) based on the doses in previous studies in rats^[21]. Body weight was
221 monitored daily. Loss of weight was observed in the virus infected group, and
222 administration of VO-extract significantly alleviated this infection-induced weight loss
223 for both the low and the high dose (Figure 1B). Using H&E staining in lung sections,
224 we next examined changes in alveolar morphology and immune cell infiltration on day
225 3 post viral infection. We observed massive infiltration of immune cells along with
226 thickening of alveolar walls and disrupted lung parenchyma in virus-infected mice
227 (Figure 1C, Virus group vs. Control group). These infection-induced symptoms in lung
228 was considerably reduced by the administration of VO-extract for low and high doses
229 (Figure 1C, Low/High group vs. Virus group). Intriguingly, the low dose seemed to
230 achieve a better attenuation of the symptoms relative to the high dose (Figure 1C, Low

231 group vs High group). Along the same line, viral infection-triggered release of the
232 inflammatory cytokines (TNF- α , IL-1 β and IL-6) was abolished by the administration
233 of VO-extract to a comparable level as Control group (Figure 1D). No difference was
234 identified between high and low doses (Figure 1D). Taken together, our findings
235 indicate that VO-extract is a potent agent to dampen infection-induced acute lung
236 damage and inflammatory response.



237

238 **Figure 1.** Analysis of the effects of VO-extract on infection-induced acute lung damage and
239 inflammation *in vivo*. (A) C57BL/6J mice were challenged intranasally with influenza virus
240 A/PR8/34 (H1N1) (100 PFU) on day 0, followed by oral administration with a single dose of
241 VO-extract (low dose/Low: 0.5 g/kg; high dose/High: 1 g/kg) every day for three days. Mice
242 were sacrificed on day 3. (B) Viral infection caused loss of body weight was ameliorated by
243 VO-extract. Body weight of mice was measured every day for three days. n = 8 for each group.
244 (C) Administration of VO-extract alleviated virus-induced inflammation in lung. Histological
245 analysis of lung tissue was carried out on day 3. Two magnifications are shown: 100 \times (scale
246 bars: 100 μ m) and 200 \times (scale bars: 100 μ m). One representation sample from each group is
247 shown (n = 3). a total of 50 alveoli were counted on each slide at \times 200 magnification (n=3).
248 (D) Administration of VO-extract abolished viral infection triggered release of
249 proinflammatory cytokines. Blood samples were taken on day 3. Cytokine concentration was
250 determined using ELISA. SPSS version 19.0 and the GraphPad Prism software 5.0 were used
251 for statistical analysis. Results are shown as mean \pm SD.

252 3.2. *VO-extract promotes infection-induced maturation and activation of NK cells in*

253 *the lungs*

254 NK cells are key players to eliminate pathogen-infected cells. We next analyzed the

255 impact of VO-extract on NK functions. For this purpose, we quantified the frequency

256 and activation of the NK cells isolated from the lung tissue on day 3 post-infection. We

257 found no alteration in the frequency of lung-residing NK cells by administration of VO-

258 extract (Figure 2A, B). To further evaluate NK cell activation, we used surface markers

259 CD11b and CD69, as expression of CD11b is positively associated with effector

260 functions of murine NK cells^[23] and expression of CD69 is induced in activated NK

261 cells and contribute to their cytotoxic functions^[24]. We found that viral infection

262 substantially enhanced the frequency of the CD11b⁺ NK subset, and this tendency was

263 further elevated by administration of the low dose of VO-extract but not altered by the

264 high dose (Figure 2A, C). A similar effect was also observed for the CD69⁺ NK subset

265 (Figure 2A, D). These results indicate that only low dose of VO-extract promote viral

266 infection-induced activation of NK cells.




Figure 2. Low dose of VO-extract enhances NK activation in response to viral infection.

C57BL/6J mice were challenged intranasally with virus (influenza virus A/PR8/34 (H1N1), 100 PFU) on day 0, followed by oral administration with a single dose of VO-extract (Low: 0.5 g/kg; High: 1 g/kg) every day for three days. Lung samples were collected on day 3. NK cells from lungs were examined using flow cytometry. SPSS version 19.0 and the GraphPad Prism software 5.0 were used for statistical analysis.


3.3. Identification of chemical composition from VO-extract by UPLC-Q-TOF-MS

To identify the active ingredients in VO-extract, we performed ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS). A representative base peak chromatogram (BPC) of VO-extract based on the positive and negative ion modes is shown in Figure 3. A total number of thirteen ingredients were successful identified: 3,4-dihydroverbenalin, Verbeofflin I, Hastoatoside, Verbenaloside, Quercetin, Acteoside, Luteolin, Isorhamnetin, Luteolin 7-

282 O- β -gentiobioside, Isoacteoside, Leucosceptoside A, Apigenin, Kaempferol
283 (Supplementary Table 1).

284

285



286


287

288 **Figure 3.** The chemical base peak intensity (BPI) chromatogram of key compounds
289 characterization of VO-extract in positive ion mode and negative ion mode determined by
290 UPLC-Q-TOF/MS. Identification No.: 3,4-dihydroverbenalin (1); Verbeofflin I (2); Hastatoside
291 (3); Verbenaloside (4); Quercetin (5); Acteoside (6); Luteolin (7); Isorhamnetin (8); Luteolin
292 7-O- β -gentiobioside (9); Isoacteoside (10); Leucosceptoside A (11); Apigenin (12);
293 Kaempferol (13).

294 *3.4. Bioactive components of *V. officinalis* enhance NK killing efficiency*

295 In order to verify the impact of bioactive constituents of *V. officinalis* on NK effector
296 functions, we cultured primary human NK cells with the corresponding compound (10
297 μ M and 30 μ M) for three days in presence with IL-2. First, we analyzed killing kinetics
298 of NK cells using a plate-reader based real-time killing assay [Error! Reference source not found.](#).

299 We found that Acteoside, Apigenin, and Kaempferol slightly reduced NK killing
300 efficiency, whereas Verbenalin and Hastatoside enhanced NK killing efficiency (Figure
301 4A). Verbenalin exhibited the highest potency for elevation of NK killing efficiency
302 (Figure 4A). We further verified the impact of Verbenalin on NK killing efficiency in
303 3D. Target cells expressing FRET-based apoptosis reporter pCasper were embedded in
304 collagen matrix and NK cells were added from the top. Target cells were yellow when
305 alive and turned green when undergoing apoptosis [Error! Reference source not found.](#). Results
306 show that Verbenalin-treated NK cells exhibited significantly faster killing kinetics
307 compared to their counterparts treated with vehicle. Thus, we conclude that among the
308 bioactive constituents of *V. officinalis*, Verbenalin is able to increase NK killing
309 efficiency under a physiologically relevant condition.




325 **Figure 4. Bioactive constituents of Verbena differentially regulated NK killing efficiency.**
326 (A) Kinetics of NK killing affected by bioactive constituents of *V. officinalis*. were determined
327 with real-time killing assay. (B, C) Verbenalin accelerates NK killing kinetics in 3D. Selected
328 time points are shown in B and the change in live target cells is shown in C. Scale bars are 40
329 μm. One representative donor out of four is shown.

330


331 *3.5. Verbenalin accelerated NK killing processes*

332 Next, we sought for the underlying mechanisms of increase in NK killing efficiency
333 by Verbenalin. We examined proliferation, expression of cytotoxic proteins (perforin
334 and granzyme B), and degranulation of lytic granules. None of those processes were
335 affected by Verbenalin (Figure 5A-C). We then analyzed the times required for killing
336 by visualization of the killing events with high-content imaging setup every 70 sec for
337 12 hours (Figure 6A, Movie 1). The time between initiation of NK/target contact and
338 target cell apoptosis was analyzed for randomly chose NK cells. The quantification
339 shows that the time required for killing was considerably reduced by Verbenalin-
340 treatment (Figure 6B). Concomitantly, on average, the numbers of target cells killed per
341 NK cell was almost doubled for Verbenalin-treated NK cells relative to their vehicle-
342 treated counterpart (Figure 6C). Notably, it is reported that a portion of NK cells can
343 serve as serious killers, which are able to kill several target cells in a row ^{Error! Reference}
344 **source not found.** We thus also analyzed the frequency of serial killers (one NK killed more
345 than one target cell), single killers (one NK killed only one target cell) and non-killers
346 (NK cells did not kill any target cells). We found that Verbenalin-treatment substantially
347 enhanced the portion of serial killers and concomitantly reduced the portion of non-
348 killers (Figure 6D). Taken together, our results suggest that Verbenalin potentiates NK
349 cell activation upon target recognition, shortening the time required to initiate
350 destruction of target cells, therefore enhancing killing efficiency of NK cells.
351



352

353 **Figure 5. Proliferation and lytic granule pathway of NK cells were not affected by**
 354 **Verbenalin.** Primary human NK cells were stimulated with IL-2 in presence of Verbenalin with
 355 indicated concentrations for 3 days prior to experiments. (A) Proliferation of NK cells. One
 356 representative donor out of four is shown. (B, C) Expression of cytotoxic proteins. Expression
 357 of perforin (B) and granzyme B (C) was determined by flow cytometry. Results are from four
 358 donors. (D) Release of lytic granules was determined with CD107a degranulation assay. Results
 359 are from four donors. ns: not significant. Paired Student's t-test was used for statistical analysis.
 360



361

362 **Figure 6. Verbenalin shortened the time required for killing and increases average kills**
 363 **per NK.** Primary human NK cells were stimulated with IL-2 in presence of Verbenalin with
 364 indicated concentrations for 3 days prior to experiments. Target cells (K562-pCaspar) were
 365 embedded in collagen and NK cells were added from top. Killing events were visualized at
 366 37°C every 70 sec. (A) NK cells make multiple contacts with target cells. One representative
 367 NK cell from each condition is shown. NK cells (marked in red) were not fluorescently labeled.
 368 The target cells in contact with the corresponding NK cell are numbered. Scale bars are 20 μm.
 369 (B) Verbenalin shortens the time required for killing. The period from NK/target contact to
 370 target apoptosis was quantified. (C) Verbenalin-treatment enhances number of target cells killed

371 per NK cell. (D) Fraction of serial killers is elevated by Verbenalin treatment. Fraction of serial
372 killer (one NK killed more than one target cell), single killer (one NK killed only one target
373 cell) and non-killer (NK cells did not kill any target cells) for each donor was analyzed. Results
374 are from two donors. 21 NK cells were randomly chosen from each condition. Mann-Whitney
375 test was used for statistical analysis.

376

377 **4. Discussion**

378 Uncontrolled immune responses induced by infection is often correlated with life-
379 threatening consequences such as respiratory failure due to lung damage and cytokine-
380 storm syndrome. In this process, exacerbated inflammatory responses initiated by the
381 innate immunity play an essential role. Thus, early interventions minimizing undesired
382 inflammation without sabotaging immune responses to fight pathogens are of great
383 significance to achieve optimal clinical outcome. In this work, we demonstrate that the
384 extract of *V. officinalis*, a medical herb with a long history of utilization in traditional
385 Chinese medicine and alternative medicine in western countries, significantly reduces
386 viral infection-induced acute lung damage as well as release of proinflammatory
387 cytokines. At the same time, administration of low dose of VO-extract can considerably
388 enhance NK activation in response to viral infection. In addition, we have identified
389 that Verbenalin, a biologically active constituent from *V. officinalis*, substantially
390 elevated NK cell-mediated cytotoxicity by shortening the time required for killing and
391 consequently enhancing the frequency of serial killers. These findings suggest *V.*
392 *officinalis* and Verbenalin as promising therapeutic agents for early intervention to
393 protect lung function, avoid cytokine storm, and facilitate clearance of virus-infected
394 cells.

395 The use of the *V. officinalis* herb in modern phytotherapy is grounded in its use in

396 folk medicine across different continents including Europe, Asia, America and
397 Australia **Error! Reference source not found.** Recently, a newly developed formula Xuanfei
398 Baidu composed of thirteen medical herbs including *V. officinalis* has shown very
399 positive clinical outcome treating COVID-19 patients **Error! Reference source not found.** *V.*
400 *officinalis* has traditionally been used to treat topical inflammation^[30] and chronic
401 generalized gingivitis **Error! Reference source not found.**
402 In this study, we demonstrated that VO-extract could relieve lung injury induced by
403 influenza virus A. The effect of VO extract can be a combined result from various levels.
404 It is reported that treatment of *V. officinalis* inhibits the replication of respiratory
405 syncytial virus**Error! Reference source not found.**, suggesting that active constituents of *V.*
406 *officinalis* can inhibit viral replication or induce destruction of virus. We administrated
407 VO-extract intragastrically and the concentration in lung might reach the levels to affect
408 viral replication to some extent. In addition, it is reported that treatment of active
409 constituents of *V. officinalis* *in vitro* increases phagocytotic activity of neutrophils^[32].
410 We postulate that viral particles in lungs can be removed more efficiently by neutrophils
411 in the VO-extract-treated group.

412 Massive infiltration of innate immune cells, especially neutrophils and macrophages,
413 into the infected lung tissue is required to remove viral particles, however reactive
414 oxygen species (ROS), nitric oxide (NO), IL-6 and TNF- α released by these cells can
415 lead to damage of endothelial/epithelial cells^[33]. Proinflammatory cytokines are the
416 triggers to recruit these cells to inflammation sites. We found that the levels of TNF- α ,
417 IL-1 β and IL-6 in serum were reduced when treated with VO-extract. TNF- α can be

418 released by M1-type macrophages and T cells ^[35], mainly regulated by the NF-κB
419 pathway ^[36]. IL-1 β is released most commonly by monocytes, macrophages, and mast
420 cells; however, non-immune cells, such as neuronal and glial cells, can synthesize and
421 release IL-1 β during cell injury or inflammation ^[37]. Sentinel cells of the innate immune
422 system (macrophages and monocytes) are a major source of IL-1 β , but many other cell
423 types, including epithelial cells, endothelial cells, and fibroblasts, can also produce IL-
424 β . IL-1 β is regulated by the NF-κB, c-Jun N-terminal kinase (JNK), and p38 MAPK
425 pathways Error! Reference source not found.. IL-6 can be released by myocardial and immune
426 cell ^[39], mainly triggered and regulated by signalling pathways like NF-κB and MAPK
427 ^[40]. It is reported that total glucosides of *V. officinalis* attenuate chronic nonbacterial
428 prostatitis in rat model by reducing the release of IL-2, IL-1 β and TNF- α in prostate^[41].
429 Verbenalin, a bioactive constituent of *V. officinalis*, can effectively reduce airway
430 inflammation in asthmatic rats by inhibiting the activity of NF-κB/MAPK signalling
431 pathway ^[42]. These above-mentioned pathways and molecules can be possible targets
432 for *V. officinalis* to regulate proinflammatory cytokine release.

433 In this work, we observed that the duration from establishment of NK/target contact
434 to the destruction of target cells was shortened for Verbenalin-treated NK cells relative
435 to their counterpart. To successfully execute their killing function, NK cells need to
436 identify their target cells using surface receptors, followed by formation of a tight
437 junction termed the immunological synapse between the NK cell and the target cells.
438 Consequently, lytic granules (LG) in NK cells, which contain cytotoxic protein such as
439 pore-forming protein perforin and serine proteases granzymes, are enriched and

440 released at the IS to induce destruction of target cell^[43]. Thus, the duration required for
441 killing is determined by at least five steps: engagement of surface activating/inhibitory
442 receptors, formation of the intimate contact, enrichment of lytic granules, release of
443 lytic granules, and uptake of cytotoxic proteins by target cells.

444 NK cells express activating receptors and inhibitory receptors to govern NK
445 activation^[45]. Engagement of activating receptors, such as NKp46, NKp30, NKp44 and
446 NKG2D, triggers signaling pathways for NK activation^[46]. Inhibitory receptors engage
447 with major histocompatibility complex (MHC) Class I molecules, which are expressed
448 on all healthy self-cells. Loss or down-regulation of MHC-I molecules results in
449 activation of NK cells to initiate the corresponding killing processes^[47]. Formation of
450 the intimate contact between NK cells and target cells are largely dependent on LFA-
451 1/ICAM-1 interaction^[48]. Enrichment of cytotoxic protein-containing LGs at the
452 synapse is regulated by reorganization of cytoskeleton, especially reorientation of
453 MTOC towards the contact site^[49]. LG release requires proper granule docking at the
454 plasma membrane and vesicle fusion with the plasma membrane. Transportation and
455 release of LGs are tightly regulated by SNARE and related proteins^[50]. Uptake of
456 cytotoxic proteins by target cells requires Ca^{2+} dependent endocytosis^[52]. Enhancement
457 in any of the above-mentioned steps could accelerate killing processes. For example,
458 sensitize activating receptors and/or up-regulation of effector molecules down-stream
459 of activating receptors, promote LG accumulation at the IS, reduce dwell time for
460 docking, or enhance efficiency of LG release. To identify which step(s) are affected by
461 verbenalin to accelerate killing requires further investigation.

462 **5. Conclusions**

463 The present study demonstrated that VO-extract could relieve lung injury induced
464 by influenza virus A and promote the maturation and activation of lung NK cells.
465 Moreover, our *in vitro* study with primary human NK cells from peripheral blood
466 mononuclear cells further suggested Verbenalin significantly reduced contact time
467 required for killing therefore enhancing total killing events per NK cell. These findings
468 established a direct link between Verbenalin, a bioactive constituent of VO-extract, and
469 killing efficiency of NK cells. It indicates that as a compound, Verbenalin has a
470 promising potential for therapeutical applications fighting against cancer and/or
471 infection.

472

473 **Declarations**

474 **Abbreviations**

475 IS: immunological synapse;

476 LG: lytic granules;

477 MHC: major histocompatibility complex;

478 NK: Natural killer;

479 PBMCs: peripheral blood mononuclear cells;

480 VO-extract: *Verbena officinalis L.* extract.

481 **Ethics approval and consent to participate**

482 Research carried out for this study with material from healthy donors (leukocyte
483 reduction system chambers from human blood donors) is authorized by the local ethic
484 committee (declaration from 16.4.2015 (84/15, Prof. Dr. Rettig-Stürmer).

485 **Consent for publication**

486 Not applicable.

487 **Availability of data and materials**

488 The datasets used and/or analyzed during the current study are available from the
489 corresponding author upon reasonable request.

490 **Competing interests**

491 The authors have no financial conflicts of interest.

492 **Funding**

493 This project was funded by National Key R&D Program of China (No.
494 2021YFE0200300 to Y.W., and No. 2020YFA0708004 to H.Z.), by Tianjin University

495 of Traditional Chinese Medicine (No.YJSKC-20211015) , by the Deutsche
496 Forschungsgemeinschaft (SFB 1027 A2 to B.Q., Forschungsgroßgeräte (GZ: INST
497 256/423-1 FUGG for the flow cytometer, and GZ: INST 256/429-1 FUGB for
498 ImageXpress), by the Leibniz-Gemeinschaft (INM Fellow to B.Q.) and by the National
499 Natural Science Foundation of China (No. 82204878 to R.S.).

500 **Authors' contributions**

501 RS, HZ, YW and BQ conceived this study. XZ, RZ and AY performed the experiments.
502 RS conducted the network pharmacology analysis. ZX conducted the molecular
503 docking verification. RS and BQ wrote the manuscript. RS, XZ and RZ edited pictures.
504 YW and XD revised the manuscript. All authors read and approved the final manuscript.

505 **Acknowledgments**

506 We thank the Institute for Clinical Hemostaseology and Transfusion Medicine at
507 Saarland University for providing donor blood; Carmen Hässig, Cora Hoxha, and
508 Gertrud Schäfer for excellent technical help, Markus Hoth for inspiring discussion and
509 continuous support, as well as K562-pCasper cells (with Eva C. Schwarz).

510 **References**

511 [1] Kubica P, Szopa A, Kokotkiewicz A, Miceli N, Taviano MF, Maugeri A, Cirmi S,
512 Synowiec A, Gniewosz M, Elansary HO, Mahmoud EA, El-Ansary DO, Nasif O,
513 Luczkiewicz M, Ekiert H. Production of Verbascoside, Isoverbascoside and
514 Phenolic Acids in Callus, Suspension, and Bioreactor Cultures of *Verbena*
515 *officinalis* and Biological Properties of Biomass Extracts. *Molecules*. 2020 Nov
516 28;25(23):5609.

517 [2] Khan AW, Khan AU, Ahmed T. Anticonvulsant, Anxiolytic, and Sedative Activities
518 of *Verbena officinalis*. *Front Pharmacol.* 2016 Dec 21;7:499.

519 [3] Kubica P, Szopa A, Dominiak J, Luczkiewicz M, Ekiert H. *Verbena officinalis*
520 (Common Vervain) - A Review on the Investigations of This Medicinally Important
521 Plant Species. *Planta Med.* 2020 Nov;86(17):1241-1257.

522 [4] Kubica P, Szopa A, Ekiert H. Production of verbascoside and phenolic acids in
523 biomass of *Verbena officinalis* L. (vervain) cultured under different in vitro
524 conditions. *Nat Prod Res.* 2017 Jul;31(14):1663-1668.

525 [5] Shu J, Chou G, Wang Z. Two new iridoids from *Verbena officinalis* L. *Molecules.*
526 2014 Jul 18;19(7):10473-9.

527 [6] Casanova E, García-Mina JM, Calvo MI. Antioxidant and antifungal activity of
528 *Verbena officinalis* L. leaves. *Plant Foods Hum Nutr.* 2008 Sep;63(3):93-7.

529 [7] Lopez-Jornet P, Camacho-Alonso F, Gómez-Garcia F, Molina Miñano F, Cañas X,
530 Serafín A, Castillo J, Vicente-Ortega V. Effects of potassium apigenin and verbena
531 extract on the wound healing process of SKH-1 mouse skin. *Int Wound J.* 2014
532 Oct;11(5):489-95.

533 [8] Speroni E, Cervellati R, Costa S, Guerra MC, Utan A, Govoni P, Berger A, Müller
534 A, Stuppner H. Effects of differential extraction of *Verbena officinalis* on rat
535 models of inflammation, cicatrization and gastric damage. *Planta Med.* 2007
536 Mar;73(3):227-35.

537 [9] Gazit R, Gruda R, Elboim M, Arnon TI, Katz G, Achdout H, Hanna J, Qimron U,
538 Landau G, Greenbaum E, Zakay-Rones Z, Porgador A, Mandelboim O. Lethal

539 influenza infection in the absence of the natural killer cell receptor gene Ncr1. *Nat*
540 *Immunol.* 2006 May;7(5):517-23.

541 [10] Nogusa S, Ritz BW, Kassim SH, Jennings SR, Gardner EM. Characterization of
542 age-related changes in natural killer cells during primary influenza infection in
543 mice. *Mech Ageing Dev.* 2008 Apr;129(4):223-30.

544 [11] Stein-Streilein J, Guffee J. In vivo treatment of mice and hamsters with antibodies
545 to asialo GM1 increases morbidity and mortality to pulmonary influenza infection.
546 *J Immunol.* 1986 Feb 15;136(4):1435-41.

547 [12] Zhou G, Juang SW, Kane KP. NK cells exacerbate the pathology of influenza virus
548 infection in mice. *Eur J Immunol.* 2013 Apr;43(4):929-38.

549 [13] Abdul-Careem MF, Mian MF, Yue G, Gillgrass A, Chenoweth MJ, Barra NG,
550 Chew MV, Chan T, Al-Garawi AA, Jordana M, Ashkar AA. Critical role of natural
551 killer cells in lung immunopathology during influenza infection in mice. *J Infect*
552 *Dis.* 2012 Jul 15;206(2):167-77.

553 [14] Kong L, Deng J, Zhou X, Cai B, Zhang B, Chen X, Chen Z, Wang W. Sitagliptin
554 activates the p62-Keap1-Nrf2 signalling pathway to alleviate oxidative stress and
555 excessive autophagy in severe acute pancreatitis-related acute lung injury. *Cell*
556 *Death Dis.* 2021;12(10):928.

557 [15] Schmidt J, Rattner D, Lewandrowski K, Compton C, Mandavilli U, Knoefel W,
558 et al. A better model of acute pancreatitis for evaluating therapy. *Ann Surg.*
559 1992;215:44-56.

560 [16] Matute-Bello G, Winn R, Jonas M, Chi E, Martin T, Liles W. Fas (CD95) induces

561 alveolar epithelial cell apoptosis in vivo: implications for acute pulmonary
562 inflammation. *Am J Pathol.* 2001;158:153–61.

563 [17] Kummerow C, Schwarz EC, Bufe B, Zufall F, Hoth M, Qu B. A simple, economic,
564 time-resolved killing assay. *Eur J Immunol.* 2014 Jun;44(6):1870-2.

565 [18] Zhao R, Zhou X, Khan ES, Alansary D, Friedmann KS, Yang W, Schwarz EC, Del
566 Campo A, Hoth M, Qu B. Targeting the Microtubule-Network Rescues CTL
567 Killing Efficiency in Dense 3D Matrices. *Front Immunol.* 2021 Aug 17;12:729820.

568 [19] Domizio JD, Gulen MF, Saidoune F, Thacker VV, Yatim A, Sharma K, Nass T,
569 Guenova E, Schaller M, Conrad C, Goepfert C, de Leval L, Garnier CV,
570 Berezowska S, Dubois A, Gilliet M, Ablasser A. The cGAS-STING pathway drives
571 type I IFN immunopathology in COVID-19. *Nature.* 2022 Mar;603(7899):145-151.

572 [20] Kiener M, Roldan N, Machahua C, Sengupta A, Geiser T, Guenat OT, Funke-
573 Chambour M, Hobi N, Kruithof-de Julio M. Human-Based Advanced in vitro
574 Approaches to Investigate Lung Fibrosis and Pulmonary Effects of COVID-19.
575 *Front Med (Lausanne).* 2021 May 7;8:644678.

576 [21] Fateh AH, Mohamed Z, Chik Z, Alsalahi A, Md Zin SR, Alshawsh MA. Prenatal
577 developmental toxicity evaluation of *Verbena officinalis* during gestation period in
578 female Sprague-Dawley rats. *Chem Biol Interact.* 2019 May 1;304:28-42.

579 [22] Fateh AH, Mohamed Z, Chik Z, Alsalahi A, Md Zain SR, Alshawsh MA.
580 Mutagenicity and genotoxicity effects of *Verbena officinalis* leaves extract in
581 Sprague-Dawley Rats. *J Ethnopharmacol.* 2019 May 10;235:88-99.

582 [23] Laura Chiossone, Julie Chaix, Nicolas Fuseri, Claude Roth, Eric Vivier, Thierry

583 Walzer; Maturation of mouse NK cells is a 4-stage developmental program. Blood
584 2009; 113 (22): 5488–5496.

585 [24] Borrego F, Robertson MJ, Ritz J, Peña J, Solana R. CD69 is a stimulatory receptor
586 for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor.
587 Immunology. 1999 May;97(1):159-65.

588 [25] Backes CS, Friedmann KS, Mang S, Knörck A, Hoth M, Kummerow C. Natural
589 killer cells induce distinct modes of cancer cell death: Discrimination,
590 quantification, and modulation of apoptosis, necrosis, and mixed forms. J Biol
591 Chem. 2018 Oct 19;293(42):16348-16363.

592 [26] Bhat R, Watzl C. Serial killing of tumor cells by human natural killer cells--
593 enhancement by therapeutic antibodies. PLoS One. 2007 Mar 28;2(3):e326.

594 [27] Prager I, Liesche C, van Ooijen H, Urlaub D, Verron Q, Sandström N, Fasbender
595 F, Claus M, Eils R, Beaudouin J, Önfelt B, Watzl C. NK cells switch from granzyme
596 B to death receptor-mediated cytotoxicity during serial killing. J Exp Med. 2019
597 Sep 2;216(9):2113-2127.

598 [28] Vogl S, Picker P, Mihaly-Bison J, Fakhrudin N, Atanasov AG, Heiss EH, Wawrosch
599 C, Reznicek G, Dirsch VM, Saukel J, Kopp B. Ethnopharmacological in vitro
600 studies on Austria's folk medicine--an unexplored lore in vitro anti-inflammatory
601 activities of 71 Austrian traditional herbal drugs. J Ethnopharmacol. 2013 Oct
602 7;149(3):750-71.

603 [29] Xiong WZ, Wang G, Du J, Ai W (2020) Efficacy of herbal medicine (Xuanfei
604 Baidu decoction) combined with conventional drug in treating COVID-19: A pilot

605 randomized clinical trial. Integrative medicine research 9: 100489.

606 [30]Calvo MI. Anti-inflammatory and analgesic activity of the topical preparation of
607 Verbena officinalis L. J Ethnopharmacol. 2006 Oct 11;107(3):380-2.

608 [31]Grawish ME, Anees MM, Elsabaa HM, Abdel-Raziq MS, Zedan W. Short-term
609 effects of Verbena officinalis Linn decoction on patients suffering from chronic
610 generalized gingivitis: Double-blind randomized controlled multicenter clinical
611 trial. Quintessence Int. 2016;47(6):491-8.

612 [32]Ross SM. An integrative approach to rhinosinusitis in children, part II. Holist Nurs
613 Pract. 2010 Jan-Feb;24(1):49-51.

614 [33]Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, Tang H, Nishiura K, Peng J, Tan
615 Z, Wu T, Cheung KW, Chan KH, Alvarez X, Qin C, Lackner A, Perlman S, Yuen
616 KY, Chen Z. Anti-spike IgG causes severe acute lung injury by skewing
617 macrophage responses during acute SARS-CoV infection. JCI Insight. 2019 Feb
618 21;4(4):e123158.

619 [34]Yi T, Ding W, Hao Y, Cen L, Li J, Shi X, Wang T, Chen D, Zhu H. Neutrophil
620 extracellular traps mediate severe lung injury induced by influenza A virus H1N1
621 in mice coinfecte with *Staphylococcus aureus*. Microb Pathog. 2022
622 May;166:105558.

623 [35]Tian X, Eikmans M, Hoorn MV. The Role of Macrophages in Oocyte Donation
624 Pregnancy: A Systematic Review. Int J Mol Sci. 2020 Jan 31;21(3):939.

625 [36]Maeda S, Omata M. Inflammation and cancer: role of nuclear factor-kappaB
626 activation. Cancer Sci. 2008 May;99(5):836-42.

627 [37]Fontenelle TPC, Lima GC, Mesquita JX, Lopes JLS, de Brito TV, Vieira Júnior
628 FDC, Sales AB, Aragão KS, Souza MHL, Barbosa ALDR, Freitas ALP. Lectin
629 obtained from the red seaweed *Bryothamnion triquetrum*: Secondary structure and
630 anti-inflammatory activity in mice. *Int J Biol Macromol.* 2018 Jun;112:1122-1130.

631 [38]Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. *Sci Signal.* 2010 Jan
632 19;3(105):cm1.

633 [39]Koppinger MP, Lopez-Pier MA, Skaria R, Harris PR, Konhilas JP. *Lactobacillus*
634 *reuteri* attenuates cardiac injury without lowering cholesterol in low-density
635 lipoprotein receptor-deficient mice fed standard chow. *Am J Physiol Heart Circ
636 Physiol.* 2020 Jul 1;319(1):H32-H41.

637 [40]Viji V, Shobha B, Kavitha SK, Ratheesh M, Kripa K, Helen A. Betulinic acid
638 isolated from *Bacopa monniera* (L.) Wettst suppresses lipopolysaccharide
639 stimulated interleukin-6 production through modulation of nuclear factor-kappaB
640 in peripheral blood mononuclear cells. *Int Immunopharmacol.* 2010
641 Aug;10(8):843-9.

642 [41]WANG L L, LI H B, MIAO M S. Effect of total glucosides of *Verbena officinalis*
643 L. on rat model for chronic nonbacterial prostatitis[J]. *China Medical Herald*, 2016,
644 13(16):4-7.

645 [42]DONG Shu-min, GAO Peng-hui, LIANG Wen-hua. Effects of Verbenalin on
646 Airway Inflammation,Airway Smooth Muscle Cell Proliferation and RhoA
647 Expression in Rats with Bronchial Asthma Through NF-κB/MAPK Signaling
648 Pathway[J]. *Guiding Journal of Traditional Chinese Medicine and Pharmacy*,

649 2021;27(3):23-27.

650 [43]Prager I, Watzl C. Mechanisms of natural killer cell-mediated cellular cytotoxicity.
651 J Leukoc Biol. 2019 Jun;105(6):1319-1329.

652 [44]Orange JS. Formation and function of the lytic NK-cell immunological synapse.
653 Nat Rev Immunol. 2008 Sep;8(9):713-25.

654 [45]Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, Kershaw MH. Activating and
655 inhibitory receptors of natural killer cells. Immunol Cell Biol. 2011 Feb;89(2):216-
656 24.

657 [46]Lanier LL. On guard--activating NK cell receptors. Nat Immunol. 2001
658 Jan;2(1):23-7.

659 [47]Sivori S, Vacca P, Del Zotto G, Munari E, Mingari MC, Moretta L. Human NK
660 cells: surface receptors, inhibitory checkpoints, and translational applications. Cell
661 Mol Immunol. 2019 May;16(5):430-441.

662 [48]Gross CC, Brzostowski JA, Liu D, Long EO. Tethering of intercellular adhesion
663 molecule on target cells is required for LFA-1-dependent NK cell adhesion and
664 granule polarization. J Immunol. 2010 Sep 1;185(5):2918-26.

665 [49]Mentlik AN, Sanborn KB, Holzbaur EL, Orange JS. Rapid lytic granule
666 convergence to the MTOC in natural killer cells is dependent on dynein but not
667 cytolytic commitment. Mol Biol Cell. 2010 Jul 1;21(13):2241-56.

668 [50]Qu B, Pattu V, Junker C, Schwarz EC, Bhat SS, Kummerow C, Marshall M, Matti
669 U, Neumann F, Pfreundschuh M, Becherer U, Rieger H, Rettig J, Hoth M. Docking
670 of lytic granules at the immunological synapse in human CTL requires Vti1b-

671 dependent pairing with CD3 endosomes. *J Immunol.* 2011 Jun 15;186(12):6894-
672 904.

673 [51]Bertrand F, Müller S, Roh KH, Laurent C, Dupré L, Valitutti S. An initial and rapid
674 step of lytic granule secretion precedes microtubule organizing center polarization
675 at the cytotoxic T lymphocyte/target cell synapse. *Proc Natl Acad Sci U S A.* 2013
676 Apr 9;110(15):6073-8.

677 [52]Tuomela K, Ambrose AR, Davis DM. Escaping Death: How Cancer Cells and
678 Infected Cells Resist Cell-Mediated Cytotoxicity. *Front Immunol.* 2022 Mar
679 23;13:867098.

680

681

Supplementary Information

682

Supplementary Table 1. Chemical constituents VO-extract detected by UPLC-Q-TOF-MS.

No.	Identification	Elemental composition	RT	Calculated mass	m/z	Fragment ions	ppm
1	3,4-dihydroverbenalin	C ₁₇ H ₂₆ O ₁₀	10.065	390.1526	413.1480[M+Na] ⁺	105.0716, 179.0733	-14.96
2	Verbeofflin I	C ₁₁ H ₁₂ O ₆	10.210	240.0634	239.0559[M-H] ⁻	139.0386, 147.0462, 195.0650	0.89
3	Hastatoside	C ₁₇ H ₂₄ O ₁₁	10.214	404.1319	403.1219[M-H] ⁻	195.0650, 223.0600, 241.0713	-1.21
					427.1216[M+Na] ⁺	165.0570, 343.0921	
4	Verbenaloside	C ₁₇ H ₂₄ O ₁₀	10.794	388.1369	387.1312[M-H] ⁻	101.0242, 179.0471, 225.0761	-1.29
					411.1267[M+Na] ⁺	149.0621, 167.0728, 195.0681	
5	Quercetin	C ₁₅ H ₁₀ O ₇	13.112	302.0427	301.0341[M-H] ⁻	151.0051, 161.0271, 179.0370	4.24
					303.0554[M+H] ⁺	163.0410, 195.0689	
6	Acteoside	C ₂₉ H ₃₆ O ₁₅	14.522	624.2054	623.1991[M-H] ⁻	161.0249, 179.0338, 461.1627, 487.1425	-1.53
					647.2083[M+Na] ⁺	163.0420, 325.0980, 471.1586	
7	Luteolin	C ₁₅ H ₁₀ O ₆	14.588	286.0477	285.0395[M-H] ⁻	255.0278, 283.0240	3.37
					287.0607[M+H] ⁺	139.0051, 153.0198	
8	Isorhamnetin	C ₁₆ H ₁₂ O ₇	14.986	316.0583	315.0493[M-H] ⁻	283.0230, 300.0252	5.48
9	Luteolin 7- <i>O</i> - β -gentiobioside	C ₂₇ H ₃₀ O ₁₆	15.169	610.1534	609.1416[M-H] ⁻	179.0375, 254.9867, 283.0317	7.4

10	Isoacteoside	$C_{29}H_{36}O_{15}$	15.898	624.2054	623.1970[M-H] ⁻	161.0245, 179.0333, 461.1645	1.84
					647.2072[M+Na] ⁺	163.0417, 325.0976	
11	Leucosceptoside A	$C_{30}H_{38}O_{15}$	16.114	638.2211	637.2177[M-H] ⁻	161.0265, 175.0410, 461.1702	-6.13
					661.2244[M+Na] ⁺	163.0421, 177.0552, 322.1341	
12	Apigenin	$C_{15}H_{10}O_5$	16.296	270.0528	269.0449[M-H] ⁻	161.0235, 179.0337	2.4
					271.0651[M+H] ⁺	163.0414	
13	Kaempferol	$C_{15}H_{10}O_6$	16.960	286.0477	285.0392[M-H] ⁻	161.0248, 179.0337	4.43

683 **Supplementary Movie 1. Verbenalin-treatment reduces time required for killing and enhances average kills per NK.** Primary human NK
 684 cells were stimulated with IL-2 in presence of Verbenalin with indicated concentrations for 3 days prior to experiments. Target cells (K562-pCaspar)
 685 were embedded in collagen and NK cells were added from top. Killing events were visualized at 37°C every 70 sec. One representative NK cell
 686 from each condition (0 μ M vs 30 μ M) is shown. NK cells were not fluorescently labeled and marked with blue tracks. The target cells in contact
 687 with the corresponding NK cell are numbered.